Review Virus Chikungunya

Authors

  • Grenshannya Anasthasya Pua Sam Ratulangi University
  • Fatimawali Fatimawali
  • Irma Antasionasti

Keywords:

Chikungunya virus, transmission, symptoms, symptomatic, treatment, vaccine.

Abstract

Chikungunya is a virus belonging to the family Togaviridae and genus Alphavirus which was first isolated in Tanzania in 1953. This virus transmission by mosquito vectors, namely Aedes aygepti and Aedes albopictus. Indonesia itself is included as the country that has the largest burden of Chikungunya in Southeast Asia. Symptoms caused by this viral infection are severe enough to cause temporary paralysis and prolonged joint pain. Chikungunya virus drugs and vaccines are not yet officially available and are licensed only in the form of symptomatic treatment that can be given to reduce symptoms. Research and development of Chikungunya virus treatment and vaccines are currently being developed to control the spread of the Chikungunya virus.

 

References

Abdelnabi, R., Neyts, J., & Delang, L. (2015). Towards Antivirals Against Chikungunya Virus. Antiviral Res. 121, 59–68.

Akahata, W., Yang, Z-Y., Andersen, H., Sun, Siyang., Holdaway, H.A., Kong, W-P., Lewis, M.G., Higgs, S., Rossmann, M.G., Rao, S., & Nabel, G.J. (2010). . A Virus-like Particle Vaccine for Epidemic Chikungunya Virus Protects Non-human Primates Against Infection. Nat Med. 16(3), 334–338.

Chang, L.J., Dowd, K.A., Mendoza, F.H., Saunders, J.G., Sitar, S., Plummer, S.H., Yamshchikov, G., Sarwar, U.N., Hu, Z., Enama, M.E., Bailer, R.T., Koup, R.A., Schwartz, R.M., Akahata, W., Nabel, G.J., Mascola, J.R., Pierson, T.C., Graham, B.S., Ledgerwood, J.E., & VRC 311 Study Team. (2014). Safety and Tolerability of Chikungunya Virus-like particle Vaccine in Healthy Adults: A Phase 1 Dose-escalation Trial. Lancet (London, England). 384(9959), 2046–2052.

Chen, K.C., Kam, Y.W., Lin, R. P.T., Ng, M.M.L., Ng, L.F., & Chu, J.H.J. (2013). Comparative Analysis of The Genome Sequences and Replication Profiles of Chikungunya Virus Isolates within The East, Central and South African (ECSA) Lineage. Virology Journal. 10(1), 169.

Clayton, A.M. Monoclonal Antibodies As Prophylactic and Therapeutic Agents Against Chikungunya Virus. J Infect Dis. 214(suppl 5), S506–S509.

Das, I., Basantray, I., Mamidi, P., Nayak, T.K., Pratheek, B.M., Chattopadhyay, S., Chattopadhyay, S. (2014). Heat Shock Protein 90 Positively Regulates Chikungunya Virus Replication by Stabilizing Viral Non-structural Protein nsP2 During Infection. PLoS One. 9(6), e100531.

Edelman, R., Tacket, C.O., Wasserman, S.S., Bodison, S.A., Perry, J.G., & Mangiafico, J.A. (2000). Phase II safety and immunogenicity study of live Chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg. 62(6), 681–685.

Galan-Huerta, K.A., Rivas-Estilla, A.M., Frenandez-Salas, I., Farfan-Ale, J.A., & Ramos-Jimenez, J. (2015). Chikungunya Virus: A General Overview. Medicina Universirata. 17(68), 175-183.

Goo, L., Dowd, K.A., Lin, T.Y., Mascola, J.R., Graham, B.S., Ledgerwood, J.E., & Pierson, T.C. (2016). A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes. The Journal of infectious diseases. 214(10), 1487–1491.

Hoque, H., Islam, R., Ghosh, S., Rahaman, M., Azad, P.N., & Miah, A. (2021). Implementation of in silico methods to predict common epitopes for vaccine development against Chikungunya and Mayaro viruses. Heliyon. 7, e06396

Horwood, P.F., & Buchy, P. (2015). Chikungunya. Revue Scientifique et Technique (International Office of Epizootics). 34(2): 479-489.

Lum, F.M., & Ng, L.F. (2015). Cellular and Molecular Mechanisms of Chikungunya Pathogenesis. Antiviral Research. 120, 165-174.

Malvy, D., Ezzedine, K., Mamani-Matsuda, M., Autran, B., Tolou, H., Receveur, M-C., Pistone, T., Rambert, J., Moynet, D., & Mossalayi, D. (2009). Destructive Arthritis in A Patient with Chikungunya Virus Infection Persistent Spesific IgM Antibodies. BMC Infect Dis. 9, 200.

McClain, D.J., Pittman, P.R., & Ramsburg, H.H. Immunologic Interference from Sequential Administration of Live Attenuated Alphavirus Vaccines. J Infect Dis. 177, 634-641.

Melton, J.V., Ewart, G.D., Weir, R.C., Board, P.G., Lee, E.. & Gage, P.W. (2002). Alphavirus 6K Protein Form Ion Channels. Journal of Biological Chemistry. 277(49), 46923-46931.

Naqvi, S., Bashir, S., Rupareliya, C., Shams, A., Giyanwani, P.R., Ali, Z., Qamar F., Kumar, V., Talib, V. (2017). Clinical spectrum of chikungunya in Pakistan. Cureus. 9, e1430.

Plante K, Wang E, Partidos CD, et al. (2011). Novel Chikungunya Vaccine Candidate with An IRES-based Attenuation and Host Range Alteration Mechanism. Plos Pathogens. 7(7), e1002142.

Plante, K.S., Rossi, S.L., Bergren, N.A., Seymour, R.L., & Weaver, S.C. (2015). Extended Preclinical Safety, Efficacy and Stability Testing of A Live-attenuated Chikungunya Vaccine Candidate. PLoS Negl Trop Dis. 9(9), e0004007.

Pramestuti, N., Sari, I.Z.R., Setiyani, E., Trisnawati, U.F., Lestari, E., & Ustiawan, A. (2021). Gambaran Epidemiologi Peningkatan Kasus Chikungunya di Desa Kajongan Kecamatan Bojongsari Kabupaten Purbalingga. BALABA. 17(2), 127-136.

Rashad, A.A., Mahalingam, S., & Keller, P. A. (2014). Chikungunya Virus: Emerging Targets and New Opportunities for Medical Chemistry. Journal of Medical Chemistry. 57(4), 1147-1166.

Roy, C.J., Adams, P., Wang, E., Plante, K., Gorxhakov, R., Seymour, R.L., Vinent-Oliphant, H., & Weaver, S.C. (2014). Chikungunya Vaccine Candidate Is Highly Attenuated and Protects Nonhuman Primates Against Telemetrically Monitored Disease Following a Single Dose. The Journal of Infectious Diseases. 209(12), 1891-1899.

Schwameis, M., Buchtele, N., Wadowski, P.P., Schoergenhofer, C., & Jilma, B. (2016). Chikungunya Vaccines in Development. Human Vaccines & Immunotherapeutics. 12(3), 716-731.

Silva, L.A., & Dermody, T.S. (2017). Chikungunya Virus: Epidemiology, Replication, Disease Mechanisms, and Prospective Intervention Strategies. The Journal of Clinical Investigation. 127(3), 737-749.

Singh, S. K., & Unni, S.K. (2011). Chikungunya Virus: Host Pathogen Interaction. Review in Medical Virology. 21(2), 78-88.

Smith, S.A., Silva, L.A., Fox, J.M., Flyak, A., Kose, N., Sapparapu, G., Khomadiak, S., Ashbrook, A.W., Kahie, K.M., Fong, R.H., Swayne, S., Doranz, B.J., McGee, C.E., Heise, M.T., Pal, P., Brien, J.D., Austin, S.K., Diamond, M.C., Dermody, T.S., & Crowe Jr, J.E. (2015). Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity Against Chikungunya Virus. Cell Host Microbe. 18(1), 86–95.

Solignat, M., Gay, B., Higgs, S., Briant, L., & Devaux, C. (2009). Replication Cycle of Chikungunya: A Re-emerging Arbovirus. Virology. 393(2), 183-197.

Metz, S.W., Gardner, J., Geertsema, C., Le, T.T., Goh, L., Vlak, J.M., Suhrbier, A., & Pijlman, G.P. (2013). Effective Chikungunya Virus-like Particle Vaccine Produced in Insect Cells. PLoS neglected tropical diseases. 7(3), e2124.

Vairo, F., Haider, N., Kock, R., Ntoumi, F., Ippolito, G., & Zumla, A. (2019). Chikungunya: Epidemiology, Pathogenesis, Clinical Features, Management, and Prevention. Infectious disease clinics of North America. 33(4), 1003–1025.

Downloads

Published

2022-12-07

How to Cite

Pua, G. A., Fatimawali, F., & Antasionasti, I. (2022). Review Virus Chikungunya. PHARMACON, 11(3), 1541–1548. Retrieved from https://ejournal.unsrat.ac.id/v3/index.php/pharmacon/article/view/40485

Issue

Vol. 11 No. 3 (2022): PHARMACON

Section

Articles

License

Copyright (c) 2022 PHARMACON

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)